Form 4: Armata Pharmaceuticals Director Acquires Stock Options

Joseph M. Patti, a director of Armata Pharmaceuticals, Inc., reports the acquisition of stock options.

Summary

• On February 5, 2025, Joseph M. Patti, a director of Armata Pharmaceuticals, Inc., acquired 54,343 stock options with an exercise price of $2.04.
• These options vest in two tranches: 50% on February 5, 2026, and the remaining 50% on February 5, 2027, contingent upon continuous service.
• The options expire on February 5, 2035.
• Following the transaction, Patti directly owns 54,343 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's acquisition could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the pharmaceutical industry.
• The vesting schedule of 50% after one year and 50% after two years is fairly standard.
• The ten-year expiration date is also typical for stock options.

Key Dates